I'm hoping the Top-Line Results are released well before the complete analysis. According to my biostatistician friend, companies typically set up their analyses and programming for the primary endpoints ahead of time and can complete that part of the analysis almost instantly upon receiving the CRO data; you just enter the data and get a result. I also understood from her that the norm is to release the TLR well before the lab work is completed and analyzed. (We were talking about releasing an update to the AD P2b/3 TLR, but I got the impression that the results for the primary endpoints commonly are published before the rest. Anavex certainly did it that way, fortunately or unfortunately, before December CTAD. More experienced biotech investors may want to confirm or correct my impression.)
With Daybue on its way, releasing the TLR sooner seems smart to me, too.
I thought today's PR was written far better than its predecessors, and I have high hopes that with Kun Jin aboard we'll get an excellent, transparent TLR. I think the data from the pediatric Rett trial is going to help, too! ;) Really looking forward to this.
After scrubbing the data base is locked and the statistical analysis for the primary endpoints can begin. The secondary and other endpoints lab work may still not be back from the labs so complete analysis can't be done until that data is received.
Market Data 
Markets 
AI
